Wave Life Sciences

WVE

Market cap $1.38B

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of directors has unanimously approved a plan to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the Redomiciliation).

Wave Life Sciences' shares dropped after its weight loss candidate failed to impress in a phase 1 study. However, this product could actually be successful if it can confirm its recent phase 1 results.

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesity candidate.

Expand NASDAQ: WVE Wave Life Sciences Today's Change (-49.84%) $-6.13 Current Price $6.17 Key Data Points Market Cap $2.3B Day's Range $5.04 - $6.48 52wk Range $5.04 - $21.73 Volume 1.5M Avg Vol 3.3M Gross Margin 79.28% Wave Life Sciences (WVE 49.84%), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.

Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE GalNAc-siRNA therapy, despite results showing improvements in body composition and continued safety and tolerability. The Phase 1 INLIGHT trial reported that a single 240 mg dose of WVE-007 produced placebo-adjusted reductions of 14.3% in visceral fat, 5% in total fat, a 2% increase in lean mass, a 3.3% reduction in waist circumference, and a 0.9% reduction in body weight after six months.

At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizing lean mass with a 2% increase.

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave Life Sciences' executive officers and whether investor losses may be recovered under federal securities laws.